When Big Pharma Walks Away: What Abandoned Patents Reveal About Pipeline Priorities
Big Pharma doesn’t just “run out” of patents. It chooses what to abandon—and what to double down on.
That’s the uncomfortable takeaway from the latest analysis at DrugPatentWatch on abandoned patents and what they reveal about pipeline priorities. When…
When Big Pharma Walks Away: What Abandoned Patents Reveal About Pipeline Priorities Read Post »
